These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Disorders of fatty acid composition and the processes of lipid peroxidation in chronic ischemic heart disease].
    Author: Kalmykova VI, Zakharova EV.
    Journal: Sov Med; 1989; (4):5-8. PubMed ID: 2762920.
    Abstract:
    The levels of lipid fractions, free and bound fatty acids, initial and end lipid peroxidation products in the blood plasma, red cell membrane resistance to hemolysis, and myocardial contractility before, during, and after therapy with lipostabil forte (0.6-1.8 g daily or 10 ml (0.5 g) i.v.) and bezafibrate (0.2 g 3 times daily) along with nitrates (10 to 30 tablets) have been examined by the routine methods in 159 patients with stable angina pectoris and postinfarction cardiosclerosis. A negative effect of high doses of nitrates on myocardial hemodynamics and fatty acid composition has been revealed, resulting in accumulation of bound fatty acids. Lipostabil has improved the patients' status, myocardial function, and lipid composition, reduced the levels of atherogenic lipids and lipid peroxidation products, as well as the concentration of fatty acids with an uneven number of C atoms, increased the fatty acid nonsaturation index and the level of medium-strand fatty acids. Improvement of the patient's condition in bezafibrate therapy has been less evident; the concentration of atherogenic lipids has been reduced, but the levels of bound fatty acids and of lipid peroxidation products has increased. Bezafibrate is recommended to be administered together with antioxidants.
    [Abstract] [Full Text] [Related] [New Search]